Women fighting an aggressive form of womb cancer have been given fresh hope after a groundbreaking treatment received approval for widespread NHS use. Just 15 per cent of women manage to survive five years after being diagnosed with advanced (stage four) endometrial cancer - a disease that typically begins in the womb's lining.

The therapy, pembrolizumab, can slow cancer progression and boost survival chances, health bosses have confirmed. The National Institute for Health and Care Excellence (Nice) expects around 2,100 women to access this treatment each year.

Nice declared that its backing of the therapy for NHS England marks a "major step forward" in caring for women with this form of cancer. The medication, also branded as Keytruda and manufactured by Merck Sharp and Dohme, is an i

See Full Page